10x Genomics (TXG) Current Assets (2018 - 2026)

10x Genomics has disclosed Current Assets across 9 years of filings, most recently posting $669.7 million for Q1 2026.

• Current Assets for Q1 2026 came in at $669.7 million, up 15.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $669.7 million (up 15.52% YoY), and the FY2025 annual result was $684.5 million, up 17.12% from the prior year.
• Current Assets came in at $669.7 million for Q1 2026 at 10x Genomics, down from $684.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $697.3 million in Q1 2022 to a low of $562.3 million in Q3 2023.
• The 5-year median for Current Assets is $601.9 million (2023), against an average of $620.3 million.
• Across the five-year window, Current Assets slipped 15.41% in 2022 and rose 17.12% in 2025, its largest moves.
• 10x Genomics' Current Assets stood at $635.0 million in 2022, then decreased by 6.14% to $596.0 million in 2023, then slipped by 1.95% to $584.4 million in 2024, then grew by 17.12% to $684.5 million in 2025, then slipped by 2.15% to $669.7 million in 2026.
• The last three Current Assets figures came in at $669.7 million (Q1 2026), $684.5 million (Q4 2025), and $659.8 million (Q3 2025), per Business Quant data.